Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
January 20, 2020
Failed Alzheimer’s drug boosts CAR T-cell therapy
Engineered immune cells get a helping hand in new clinical trial for multiple myeloma patients
Highlights of Fred Hutch science in 2018
A look back at notable advances in immunotherapy, precision screening and more
Forbes '30 Under 30' lists Hutch immunotherapy researcher Alex Salter
Grad student on short list of young health care influencers
Want to make better T-cell therapies? First, figure out how they work.
New study maps out activities, effects of widely used components in cellular immunotherapies
Cancer cells BiTE the dust through SMITE-bispecific mediated T cell activation
- from the Walter's and Mehlin's labs, Clinical Research Division
Tinkering with T cells
How researchers are tweaking engineered immune cells’ cancer-targeting receptors — and why it matters
First systematic study of infections after CAR T-cell therapy
“Benchmark” research could help reduce complications of emerging immunotherapy
Mourning the loss of Dr. Oliver 'Ollie' Press
Lymphoma physician-scientist, leader and mentor made lifesaving contributions to the development of targeted cancer therapies
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
Fred Hutch immunotherapy expert comments on FDA staff review of CAR T-cell therapy
Forum at Fred Hutch focuses on the hottest developments in cancer immunotherapy
Immune-based treatments move from the fringes to the spotlight
Dissolving implant could bring immunotherapy to solid tumors
A biopolymer sponge delivers cancer-shrinking T-cell therapy in preclinical study
Tiny tech reprograms immune cells to fight cancer
Nanoparticles turn immune cells into leukemia-fighting powerhouses while they’re still inside the body
Patients with advanced lymphoma in remission after T-cell therapy
New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission
When do we say cure for cancer?
A loaded word for cancer patients, but researchers view ‘cure’ through lens of statistics
93 percent of advanced leukemia patients in remission after immunotherapy
‘Exciting’ but early results from trial of engineered immune cells